skip to main content

How Can We Help?

Short Cuts

News + Events

  • Native T-cells May Impact Cancer Immunity and Immunotherapy Native T-cells May Impact Cancer Immunity and Immunotherapy
    Most cancer immunotherapy research has targeted effector T cells, but a new study steps back and considers: What if the problem isn’t with the effector T cells, but starts higher up the cellular chain? And so researchers looked at naive T cells -- a type of immune cell that hasn’t yet been triggered to fight.
  • How studying normal cells offers insights into how cancer spreads How studying normal cells offers insights into how cancer spreads
    Healthy cells migrate only under special circumstances, such as in the early development of an embryo or when new skin cells and blood vessels move in to repair a wound. For a cancer cell to gain access to the body’s major highways -- the blood vessels and lymphatic system -- it has to invade through something.
  • Treg Cell Activity May Limit Immunotherapy Treg Cell Activity May Limit Immunotherapy
    Regulatory T cells, or Treg cells, work within the immune system to suppress immune function. Cancer immunotherapy treatments work by supercharging the immune system to fight cancer. So when Tregs come in and suppress the immune response, it shuts down the cancer-fighting effect. But eliminating the Tregs doesn’t help. Researchers have tried, but a clinical trial testing that idea showed no benefit to patients.
  • More news...
Thrive